• Neuros Medical

  Participated · Equity · Jul 2012

  Neuros Medical is a Willoughby Hills, Ohio–based neuromodulation company focused on treating intractable post-amputation pain through its proprietary Altius High-Frequency Nerve Block system. The implant consists of a cuff electrode placed around a peripheral nerve and an implantable pulse generator that delivers high-frequency electrical signals to block pain transmission. The technology, originally invented at Case Western Reserve University by Drs. Kevin Kilgore and Niloy Bhadra, targets both phantom limb pain and residual limb pain. Neuros Medical is currently running the pivotal QUEST trial, a 180-subject, randomized, double-blinded, active-sham–controlled study being conducted under an IDE to evaluate safety and effectiveness. Proceeds from the latest financing will fund completion of QUEST enrollment and preparation of a Pre-Market Approval application to the FDA. Led by President and CEO Tom Wilder, the company aims to commercialize Altius as a novel alternative to existing pain management solutions. Financial metrics such as revenue or installed base were not disclosed in the article.

• Theravasc

  Participated · Equity · Sep 2010

  TheraVasc is developing an oral, sustained-release formulation of sodium nitrite to improve blood flow and stimulate new blood-vessel growth in patients with peripheral artery disease, particularly diabetics. The company has an ongoing Phase 1 trial (started in July) that has enrolled three patients and hopes to enroll about 10 more before wrapping in November or December. It plans a Phase 2a trial at the Cleveland Clinic and University Hospitals to test efficacy in diabetics. Funding from the current raise will support the Phase 1 completion and the planned Phase 2a. The team is led by CEO Tony Giordano, who plans to split time between Cleveland and Louisiana as the company progresses. TheraVasc received a $100,000 grant from GLIDE that helped bring activity to Northeast Ohio. Management says a successful Phase 2a could position the company for acquisition or a larger venture round of $10–$20 million.

No current team members are available.